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Abstract 
 
In a recently developed human breast cancer model, treatment of tumor cells in a 3-dimensional 
culture with inhibitory β1-integrin antibody or its Fab fragments led to a striking morphological 
and functional reversion to a normal phenotype. A stimulatory β1-integrin antibody proved to be 
ineffective. The newly formed reverted acini re-assembled a basement membrane and re-
established E-cadherin–catenin complexes, and re-organized their cytoskeletons. At the 
same time they downregulated cyclin D1, upregulated p21cip,waf-1, and stopped growing. Tumor 
cells treated with the same antibody and injected into nude mice had significantly reduced 
number and size of tumors in nude mice. The tissue distribution of other integrins was also 
normalized, suggesting the existence of intimate interactions between the different integrin 
pathways as well as adherens junctions. On the other hand, nonmalignant cells when treated with 
either α6 or β4 function altering antibodies continued to grow, and had disorganized colony 
morphologies resembling the untreated tumor colonies. This shows a significant role of the 
α6/β4 heterodimer in directing polarity and tissue structure. The observed phenotypes were 
reversible when the cells were disassociated and the antibodies removed. Our results illustrate 
that the extracellular matrix and its receptors dictate the phenotype of mammary epithelial cells, 
and thus in this model system the tissue phenotype is dominant over the cellular genotype. 
 
The extracellular matrix (ECM)1 modulates breast tissue homeostasis in vivo, and has been 
shown to regulate growth, differentiation, and apoptosis of normal murine and human mammary 
epithelial cells (MEC) in culture (Barcellos-Hoff et al., 1989; Petersen et al., 1992; Strange et al., 
1992; Boudreau et al., 1995b; for review see Damsky and Werb, 1992; Adams and Watt, 1993; 
Roskelley et al., 1995). Moreover, perturbations in cell-ECM interactions are a consistent feature 
of mammary tumors and cells in vivo and in culture (Petersen et al., 1992; Bernfield et al., 1993; 
Zutter et al., 1993; Sympson et al., 1994; Bergstraesser and Weitzman, 1994; Howlett et al., 
1995). The mechanism by which ECM-mediated signal transduction events can lead to diverse 
changes in gene expression is now being unraveled. For example, it has been shown that the 
ECM mediates both biochemical and biomechanical signaling events (Roskelley et al., 1994), 
and that cell shape in turn can profoundly influence the phenotypic response of cells to the ECM 
(Dhawan and Farmer, 1994; Ingber et al., 1995). However, how alterations in these pathways 
can lead to mammary tumors is at present unknown. Because tumor cells have an altered 
response to the ECM and their microenvironment, we have argued that ECM-signaling pathways 
contain tumor suppressor checkpoints which impinge upon, and direct, cell and tissue 
architecture (Petersen et al., 1992; Howlett et al., 1994, 1995). If this were so, then the context 
and integration of adhesionderived signaling networks could dictate the final tissue phenotype 
(Bissell et al., 1982). 
 
Epithelial tissue architecture and function are orchestrated and maintained through multimeric 
adhesion complexes known to interact directly with elements of the actin and intermediate 
filament cytoskeleton, as well as with kinases and phosphatases (Schmidt et al., 1993; Hodivala 
and Watt, 1994; for review see Gumbiner 1996; Drubin and Nelson, 1996; Giancotti and 
Mainiero, 1994; Dedhar, 1995; Ashkenas et al., 1996). The mechanism whereby these adhesive 
interactions control the spatio-temporal fate of cells, and direct higher order tissue structure is 
poorly understood, although a dynamic competition between integrins and cadherins for 
polymerized actin microfilaments, and a modulation of this interaction by tyrosine kinases 
appears likely (Adams and Watt, 1993; Drubin and Nelson, 1996). Thus, the coordinated 
regulation of integrins and adherens junctions has been described during keratinocyte 
differentiation (Hodivala and Watt, 1994; Braga et al., 1995; Hotchin et al., 1995), while cell–
cell adhesion may be modulated by molecules such as fascin, an actin bundling/motility-
associated protein (Tao et al., 1996). Furthermore, the importance of β1-integrins in directing 
cell–cell and cell-ECM polarity and differentiation has been shown by studies in kidney cells 
(Ojakian and Schwimmer, 1994; Schoenenberger et al., 1994) and keratinocytes (Symington et 
al., 1993; Watt et al., 1993). Also, the redistribution of α6/β4-integrins has been reported to be 
associated with the establishment of epithelial cell polarity (Giancotti, 1996; Borradori and 
Sonnenberg, 1996), and integrin knockout studies have documented profound tissue 
degeneration and disorganization in β4-integrin null mice (Dowling et al., 1996). Thus, there is 
evidence which suggests that integrin and adherens receptor pathways direct the organization 
of epithelial tissue structure. However, how these events are coordinated, and whether there is a 
direct reciprocity or hierarchy in these interactions is not known.  
 
A common feature of mammary epithelial tumors in vivo is a disruption of tissue organization 
and polarity. Consistent with their structural function, catenin-cadherin–cytoskeletal interactions 
have been shown to be frequently altered in breast cancers, and loss of cell–cell interactions is 
associated with altered tissue organization and increased tumor invasiveness (for review see 
Takeichi, 1993; Sommers, 1996; Alford and Taylor-Papadimitriou, 1996). Although cadherins 
and catenins are often downregulated or absent in invasive breast cancers, there are many 
examples of mammary carcinoma in situ and aggressive, metastatic breast tumors in vivo that 
express the full complement of adherens proteins. Instead the cells in these tissues have 
lost their ability to assemble adherens junctions (Birchmeier and Behrens, 1993; Moll et al., 
1994; Sommers, 1996). While the precise cause(s) of this perturbation have yet to be determined, 
it has been shown that the assembly of adherens junctions can be disrupted by growth factors and 
oncogenes, and also modified by kinases and phosphatases (Warren and Nelson, 1987; D’Souza 
and Taylor-Papadimitriou, 1994; Hoschuetzky et al., 1994; Ochiai et al., 1994; Kinch et al., 
1995). This suggests that connections exist between adherens junctions and signal transduction 
pathways and implies the potential for structural plasticity. 
 
The disrupted tissue architecture observed in mammary adenocarcinoma is also frequently 
associated with alterations in integrin heterodimer profiles (D’Ardenne et al., 1991; Natali et al., 
1992; Zutter et al., 1993; Gui et al., 1995; Howlett et al., 1995). Changes in β1-, β4-, α2-, α3, and 
α6-integrins have been reported for mammary tumor cell lines and in tissue sections, and were 
shown to be associated with tissue disorganization, loss of polarity, increased tumor 
aggressiveness, and metastasis (Natali et al., 1992; Berdichevsky et al., 1994; Rossen et al., 
1994; Gui et al., 1995; Zutter et al., 1995). A relationship between altered signal transduction via 
integrins and the adherens junction pathways, and its relevance to the origin of the tumor 
phenotype has not been directly examined. This is mainly due to the lack of appropriate model 
systems in which such changes can be studied (Weaver et al., 1995). 
 
We have thus taken advantage of a unique epithelial cell model of breast cancer developed by 
Briand and coworkers (Briand et al., 1987, 1996). The HMT-3522 breast cancer series was 
established under chemically defined conditions from a breast biopsy of a woman with a 
nonmalignant breast lesion (Briand et al., 1987; Nielsen and Briand, 1989). A subline of these 
cells, generated from passage 118, became spontaneously tumorigenic after an additional 120 
passages (passage 238), while the parental line remained nontumorigenic for greater than 400 
passages (Nielsen et al., 1994; Briand et al., 1996). In this study we used nonmalignant S-1 cells 
at passage 50 (“normal”; S-1) and the tumorigenic progeny at passage 238 (T4-2; referred 
to as mt-1 in Briand et al., 1996). The latter cells were shown to have a trisomy of chromosome 
7p in addition to other genetic alterations such as a p53 mutation and a cmyc amplification 
(Madsen et al., 1992; Moyret et al., 1994; Nielsen et al., 1994; Briand et al., 1996). These two 
cell lines, one originating from the other by spontaneous genetic events, therefore, provide a 
unique tool for addressing the specific mechanisms involved in malignant conversion in 
the breast. In this paper, we postulated that if there were a cause and effect relationship between 
perturbed tissue organization, loss of cell–cell interactions and altered ECM-signaling through 
integrins on the one hand, and tumor formation on the other hand, it should be possible to modify 
morphology and behavior of these malignant cells by altering cell-ECM interactions. 
 
Here we show that modification of cell surface β1- and β4-integrins in a 3-dimensional (3-D) 
basement membrane (BM) assay (Petersen et al., 1992), influences mammary tissue 
morphogenesis and also regulates cell growth and signal transduction. Furthermore, cellular 
integrins, when normalized, promote the assembly of adherens junctions and influence the 
cytostructure of these cells, thereby implying that these two adhesion systems may be 
interconnected. Finally, our results suggest that growth as well as malignant behavior is 
regulated at the level of the tissue (acini) organization, i.e., the tissue structure appears to 
determine the phenotype which in turn overrides the cellular genotype. 
 
Materials and Methods 
 
Substrates and Antibodies 
 
Commercially prepared EHS matrix (Matrigel, Collaborative Research, Waltham, MA) was used 
for reconstituted basement membrane assays, and Vitrogen (rat tail collagen 1), ~3 mg/ml 
(Vitrogen 100, Celtrix Laboratories), was used for thinly coating the surfaces of culture dishes. 
Antibodies used for biochemical analysis and immunostaining studies were as follows: for 
immunostaining, immunoblotting, and immunoprecipitation of E-cadherin, α-catenin, and β-
catenin, we used clones 36, 29, and 14, respectively (Transduction Laboratories, Lexington, 
NY); for immunostaining of type IV collagen we used clone PHM-12 (Biogenex, San Ramon, 
CA); for immunostaining of β1- and α6-integrins we used clones AIIB2 and J1B5 (C. Damsky); 
for immunostaining of α3-integrin we used clone P1B5; for immunostaining and 
immunoprecipitation of β4-integrin we used clone 3E1; for immunoblot analysis of β1-integrin 
we used clone DF5; for immunoblot analysis of β4-integrin we used polyclonal rabbit serum; for 
immunoprecipitation of β1-integrin we used polyclonal rabbit serum (all from Chemicon 
International, Temecula, CA); for immunostaining of Ki-67 we used clone MIB; for immunoblot 
analysis of cyclin D-1 we used clone 17A6-4; and for immunoblot analysis of p21cip,waf-1 we used 
clone EA10 (all from Oncogene Science, Uniondale, NY). Fluorescence and alkaline 
phosphatase–conjugated, unlabeled, and nonspecific rat and mouse IgG’s were from Jackson 
Laboratories (West Grove, PA) and HRP-conjugated secondaries were from DAKO (Carpinteria, 
CA). Antibodies used for integrin function-altering studies within the 3-D reconstituted basement 
membrane assay were as follows: for β1-integrin functioninhibition we used clone AIIB2 (C. 
Damsky) and clone JB1a (Chemicon International); for β1-integrin function-stimulating we used 
clone TS2/16 (a kind gift of M. Hemler); for β4-integrin function-altering we used clone 
3E1 (Chemicon International); and for α6-integrin function-blocking we used clone GoH3 
(Chemicon International). 
 
Cell Culture 
 
The HMT-3522 mammary epithelial cells (Briand et al., 1987, 1996) were grown in H14 
medium (for further description see Blaschke et al., 1994) consisting of DMEM:F12 medium 
(GIBCO BRL, St. Louis, MO), containing 250 ng/ml insulin (Boehringer Mannheim, 
Indianapolis, IN), 10 µg/ml transferrin (Sigma, St. Louis, MO), 2.6 ng/ml sodium selenite 
(Collaborative Research), 10-10 M estradiol (Sigma), 1.4 x 10-6M hydrocortisone (Collaborative 
Research), and 5 µg/ml prolactin (Sigma). The S-1 cells were propagated as monolayers on 
plastic in the presence of 10 ng/ml epidermal growth factor (EGF; Collaborative Research); the 
T4-2 cells were grown as monolayers on dishes coated with collagen type I in the absence of 
EGF. Three dimensional (3D) cultures were prepared by growing S-1 and T4-2 cells to 
confluence as monolayers, followed by trypsinization and embedment into EHS matrices as 
single cells (8.5 x 105 cells/ml). Cultures were routinely grown for 10–12 d in serum-free 
medium as described above. 
 
Indirect Immunofluorescence and Immunocytochemistry 
 
EHS cultures were fixed in either 2% paraformaldehyde at ambient temperature for 20 min or in 
1:1 methanol-acetone at -20°C for 2–3 min. Specimens were embedded in sucrose, frozen in 
Tissue-Tek OCT compound (Miles Laboratories, Elkhart, IN), and 5 µ frozen sections were 
prepared for immunostaining as described previously (Streuli et al., 1991). Sections were 
incubated with primary antibodies for 60 min followed directly by either FITC or Texas red–
conjugated secondaries (45 min), or by biotinylated secondary antibodies (45 min), and either 
Texas red–conjugated streptavidin or HRP-conjugated streptavidin (30 min). Nuclei were 
counterstained with di-amino-phenyl-indole (DAPI, Sigma) or hematoxylin (5 min). Control 
sections were stained with second antibodies only. 
 
Morphogenesis Criteria 
 
Quantitative analysis of tumor cell conversion efficiency by β1-integrin function blocking 
antibodies was determined by calculating the percentage of colonies converted to a 
“nontumorigenic morphology.” Percent conversion was determined by directly examining the 
morphology, uniformity, and size of 2,000–4,000 colonies of S-1, T4-2, and β1-inhibitory 
antibodytreated T4-2 cells (T4-β1). Morphology was assessed in situ by examining the degree of 
colony organization visually by phase contrast microscopy, and by measuring colony diameter 
using an eyepiece equipped with a micrometer spindle. Colonies were deemed disorganized if 
they were both irregular in shape and the colony length exceeded the width by greater than 
twofold. Colony organization was also suggested by a lateral and radially distributed 
cytoarchitecture, which was visualized by immunostaining for the distribution of actin 
microfilaments and cytokeratin 18 intermediate filaments, and related to the distribution 
observed in acini formed by normal mammary epithelial cells. Polarity was indicated by the 
presence of a basally organized BM as determined by collagen IV and laminin immunostaining, 
and by basally immunolocalized α6-, β4-, and β1-integrins. Morphogenic reversion was scored 
positive by the deduced presence of adherens junctions as determined by colocalization of E 
cadherin and α- and β-catenins at cell–cell contacts. 
 
Analysis of Cellular Growth and Apoptosis 
 
The proliferative rate of cells in 3-D EHS was assessed by measuring the thymidine 
incorporation index. Cryosections (5 µ) of 3D cultures were pulse-labeled for 24 h with [3H]TdR 
(20 Ci/mmol, New England Nuclear Research Products, Dupont, Wilmington, DE), air dried, 
coated with Kodak NTB2 emulsion, developed, and scored visually (100–400 cells) for 
radiolabelled nuclei. Indices were calculated by expressing this value as a percentage of the total 
number of cells scored (Petersen et al., 1992). Cell growth was determined in monolayers or in 
5µ cryosections after a 12-h incubation with 10 µM BrdUrd followed by fixation in 70% ethanol, 
and staining with anti-BrdUrd using a kit (Boehringer Mannheim), and indices were calculated 
as above. Proliferative potential of 100–400 cells was assayed by immunostaining and 
calculating the Ki-67 labeling index in 5 µ cryosections of 3D EHS cultures. Proliferative status 
was determined also by counting and immunostaining the number of cells per colony as well as 
the average colony size. The colony size was measured directly in 3-D cultures by phase contrast 
microscopy using an eyepiece equipped with a micrometer spindle, which had been previously 
calibrated with a ruler. Cell number per colony was determined by counting the number of DAPI 
stained nuclei per colony in cryosections of cells in 3-D. Cell cycle status was determined by 
immunoblotting equal amounts of total cell protein lysates for cyclin D1 and p21cip,waf-1 protein 
levels after separating the proteins by reducing Laemmli gels. Apoptosis was assessed by 
detection of FITC-labeled 3'OH DNA ends using an in situ apoptosis kit (Boehringer Mannheim) 
in 5 µ cryosections (Boudreau et al., 1996). Cells were scored (150–200 cells) for the presence of 
DNA nicks and positively scored cells for each condition were expressed as a percentage of the 
total number of cells scored (apoptotic index). 
 
Determination of α- and β-Catenin-E-Cadherin Adherens Junction Assembly 
 
For the determination of total E-cadherin, α-catenin, and β-catenin levels, RIPA lysates (1% NP-
40, 0.5% deoxycholate, 0.2% SDS, 150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4 
containing 20 mM sodium fluoride, and 1 mM sodium orthovanadate, 10 µg/ml leupeptin, 10 
µg/ml pepstatin, 1 mM Pefabloc [Boehringer Mannheim], 10 µg/ml E64, 25 µg/ml aprotinin, and 
0.5 mM benzamidine) were prepared from cells isolated from EHS by PBS/EDTA, separated on 
reducing Laemmli gels and immunoblotted. For the assessment of the soluble and cytoskeletal-
associated E-cadherins, α-catenins and β-catenins, S-1, and T4-2 colonies were grown for 12 d in 
3-Dreconstituted basement membranes and colonies were isolated using icecold PBS/EDTA 
(0.01 M sodium phosphate, 138 mM sodium chloride, 5 mM EDTA), homogenized and 
fractionated into Triton X-100 soluble and insoluble lysates essentially as described by Nathke et 
al. (1994). Lysates were separated on Laemmli reducing gels and immunoblotted for adherens 
junction proteins. Densitometric analysis of scanned enhanced chemiluminescence (ECL) film 
was used for the estimation and calculation of relative protein levels. For the assessment of the β-
catenin-(or α-catenin)-E-cadherin interaction index, S-1, T4-2, and T4-β1 integrin-reverted cells 
were grown for 12 d in 3-D EHS. RIPA lysates of equal numbers of cells in EHS were prepared 
by directly homogenizing in RIPA, and were immunoprecipitated with anti–E-cadherin 
antibodies. Immunoprecipitants were separated on reducing Laemmli gels and immunoblotted 
for E-cadherin, α-catenin, and β-catenin proteins. ECL films were scanned and subjected to 
densitometric analysis for assessment of the relative protein levels. Interaction index values were 
calculated by dividing the densitometric value determined from the catenin protein 
coprecipitated with E-cadherin by the value calculated for the level of E-cadherin protein 
immunoprecipitated. For the assessment of in situ cytoskeletal-associated and soluble adherens 
junctions proteins, day 12 cultures of S-1 and T4-2 colonies were frozen (see above) without 
prior fixation, and fresh 8 µ cryosections were extracted with fresh CSK buffer (50 mM sodium 
chloride, 300 mM sucrose, 10 mM Pipes, pH 6.8, 3 mM MgCl2, 0.5% Triton X-100, containing a 
cocktail of protein inhibitors as described above). Sections were extracted for 40 min, fixed in 
2% paraformaldehyde for 20 min and immunostained for E-cadherin, α-catenin, and β-catenin 
proteins. 
 
Determination of Total Levels and Cell Surface Integrin Expression 
 
For the assessment of total β1- and β4-integrin levels, cells were grown in 3D EHS cultures for 
10–12 d, and colonies were isolated using ice-cold PBS/EDTA. Colonies were lysed in RIPA 
and equal amounts of lysate proteins were separated on reducing Laemmli gels and 
immunoblotted. ECL films were scanned and subjected to densitometric analysis for assessment 
of the relative protein levels. For the determination of colony surface β1- and β4-integrins, cells 
were grown in 3-D EHS cultures for 10–12 d and colonies were then released from the matrix by 
60–90 min incubation at 37°C with dispase (5,000 U/ml caseinolytic activity, Collaborative 
Research), washed three times in fresh DMEM:F12 medium and once in ice-cold PBS. Released 
colonies were incubated and rocked at 4°C for 60 min with 1 mg/ml sulfo-NHS-biotin (Pierce, 
Rockford, IL) in PBS to label the cell surface proteins, washed twice in ice-cold PBS containing 
50 mM glycine, and incubated for 10–15 min on ice in PBS/glycine to stop the reaction. 
Colonies were washed three more times in ice-cold PBS/glycine and lysed in 1% NP-40 lysis 
buffer also containing 120 mM sodium chloride, 50 mM Tris-HCl and 10 mg/ml leupeptin, 10 
µg/ml pepstatin, 1 mM Pefabloc (Boehringer Mannheim), 10 µg/ml E64, 25 µg/ml aprotinin, and 
0.5 mM benzamidine. Equal numbers of cells (determined by counting the cells in parallel 
cultures) or equivalent amounts of extracted proteins, were immunoprecipitated with anti–β1- or 
β4-integrin monoclonal antibodies, separated on nonreducing Laemmli gels, and immunoblotted 
for the presence of biotinylated proteins using HRP-conjugated streptavidin antibody and ECL 
detection. Irrelevant mouse or rat IgG’s served as nonspecific controls. Exposed films were 
scanned and subjected to densitometric analysis for the determination of intensity differences and 
relative quantification. 
 
Preparation of Fab Fragments 
 
Rat monoclonal AIIB2 IgG1’s were isolated using Affi-Gel Protein A Maps II system (Bio-Rad 
Labs, Hercules, CA). After purification of rat IgG1, the material was put through a 10DG 
desalting column, concentrated by centrifugation and dialyzed against 100 mM sodium acetate 
buffer, pH 5.0. Fab fragments were generated after 20 h of papain digestion (20 mU enzyme/5–
10 µg IgG protein, in 100 mM sodium acetate, pH 5.0, 50 mM cysteine, 1 mM EDTA) and 
reactions were terminated by addition of iodoacetamide. The presence of Fab fragments was 
assayed by Coomassie blue staining of acrylamide gels as well as by Western blotting using 
secondary antibodies. Completion of the reaction was monitored by the disappearance of high 
molecular weight intact antibody and the appearance of low molecular weight proteins 
comigrating with commercial Fab’s. Western blotting with anti-[Fab]2 antibodies verified the 
absence of the latter fragments in the digest. Intact AIIB2 antibody was efficiently competed out 
by the Fab preparation, as shown by solution competition and sequential immunostaining of S-1 
acini. Once the presence and activity of the Fab’s was established, samples were treated with 
sodium azide and dialyzed into DMEM:F12 before cell culture experiments. 
 
Integrin Function-altering Assays 
 
Antibodies and Fab’s and control non-immune mouse and rat IgG’s were introduced into the 
cell-embedded substratum at the time of EHS gelation. For the crude ascites of β1- and β4-
integrins, we used a range of 25–200 µg ascites protein/ml; for purified β1- and α6-integrins and 
purified mouse or rat IgG’s we used 2–25 µg/ml, ~10–150 nM. Cultures were scored visually 
after 12 d. 10–20 random fields were viewed by phase contrast microscopy and the number of 
normal spheres or tumor-like colonies were counted in each field and related to the behavior of 
control cultures either without antibodies or in the presence of irrelevant antibodies. To compare 
the reversion efficiency of various β1-integrin antibodies and Fab fragments on T4-2 cells, the 
diameter of 200 S-1 nonmalignant acini, as observed directly by phase contrast microscopy, 
+SEM was calculated and the ratio of the tumor colony diameter to the nonmalignant S-1 acini 
diameter +SEM was determined. 
 
Reversion Assay 
 
Equal densities of cells were seeded into 3-D basement membranes and were subjected to either 
β1-inhibitory integrin or mock-antibody (nonspecific rat IgG) treatment. After 12 d, cells were 
photographed, released from their matrices, and propagated as monolayers. They were then 
recultured within the 3-D basement membrane assay with or without the β1-integrin inhibitory 
antibody treatment. These steps were repeated two more times. 
 
Tumor Formation In Vivo 
 
Tumor cells were propagated as monolayers, grown for 3–4 d in a 3-D-reconstituted basement 
membrane in the absence of antibody, released by dispase (Collaborative Research), washed 
three times in DMEM:F12, and incubated with 100 µg/ml function blocking β1-integrin antibody 
(clone AIIB2), mock antibody (nonspecific rat IgG’s), or no treatment (control group) for 3 h. 
Cell colonies were then washed three times in PBS and 1–4 x 106 cells were subcutaneously 
injected into the rear flanks of 4–6-wk-old BalbC nu/nu mice, without further antibody 
treatment. Nontreated, nonmalignant S-1 cells were also injected into nude mice as negative 
controls. Statistics were done by “unistat V 4.0 for windows.” 
 
Experimental Subjects 
 
In conducting research using animals, the investigators adhered to the “Guide for the Care and 
Use of Laboratory Animals,” prepared by the Committee on Care and Use of Laboratory 
Animals of the Institute of Laboratory Animal Resources, National Research Council (NIH 
publication no. 86-23, revised 1985). In the conduct of research where human specimens were 
used, the investigators adhered to the policies regarding the protection of human subjects as 
prescribed by 32 CFR 219 and subparts B, C, and D. 
 
Results 
 
S-1 and T4-2 Cells in a 3-D Basement Membrane Culture Assay Recapitulate the 
Phenotypic Characteristics of Normal and Malignant Breast Tissue In Vivo 
 
Only small differences in morphology and growth rates could be observed between S-1 and T4-2 
cells on tissue culture plastic (not shown), but profound differences became evident after only 4 
d following their culture within a 3-D reconstituted basement membrane. Within 10 d, S-1 cells 
underwent morphogenesis and formed organized acini reminiscent of those formed by cells from 
reduction mammoplasty, while T4-2 cells formed large, loosely disorganized invasive colonies 
of cells similar to primary tumor cells tested in this assay previously (Fig. 1, a and a’; Petersen et 
al., 1992). In addition, S-1 cells were able to basally deposit and organize a basement membrane, 
as shown by immunostaining of type IV collagen (Fig. 1 b, and laminin, not shown), thereby 
demonstrating that the cells were able to form polarized structures. The irregular T4-2 colonies, 
while staining for basement membrane components had no discernible organized basement 
membrane (Fig. 1, b and b’). The failure of T4-2 cells to undergo morphogenesis was also 
indicated by their compromised cell–cell adhesion. This was shown by the absence of lateral E-
cadherin immunostaining (Fig. 1, c and c’), an increase in cytoplasmic localization of E-cadherin 
(cell fractionation and extraction studies, not shown) and reduced interaction of α- and β-catenins 
with E-cadherin (co-immunoprecipitation, Fig. 1 d). Nevertheless, the two cell types expressed 
essentially the same levels of the three cell adhesion proteins (Fig. 1 e) indicating that the 
malignant conversion was associated with compromised assembly of adherens junctions rather 
than with down-regulation of these adhesion proteins. Coincident with the formation of acini, S-
1 cells became growth arrested and exited the cell cycle, as demonstrated by negligible 
thymidine incorporation and low immunostaining for Ki-67. Consistent with their loss of 
structural organization, the tumorigenic T4-2 cells failed to growth arrest by these criteria (Fig. 
1, f and g). 
 
S-1 and T4-2 Cells Differ in the Localization and Expression of ECM Integrin Receptors 
 
We have postulated previously that tumor cells have lost their ability to respond correctly to 
ECM-induced signals (Petersen et al., 1992; Howlett et al., 1995). To determine if the loss of 
structural organization and growth control exhibited by the tumor cells was related to an 
alteration in their integrins, we characterized the integrin receptors for laminin in the two cell 
lines. While both S-1 and T4-2 cells expressed integrins β1, β4, α3, and α6, their distribution 
patterns were radically different in 3-D cultures (Fig. 2, a and a’ through d and d’). S-1 acini had 
basally distributed β1-, β4-, and α6-integrins and basolateral α3-integrin, consistent with their 
polarized phenotype. In contrast, all of these integrins were found to be randomly distributed and 
disorganized in the T4-2 colonies. Western blot analysis of the tumor colonies showed over-
expression of both β1- and β4-integrins relative to the levels observed in the S-1 acini (Fig. 3, a 
and b). Cell surface labeling and immunoprecipitation experiments revealed that the surface 
levels of β1-integrins were slightly higher (12.5%) in the T4-2 cells (Fig. 3 c) whereas the 
surface β4-integrin levels were much lower (60%) in T4-2 than in S-1 colonies (Fig. 3 d). 
However, the ratio of β1- to β4-integrins at the cell surface was increased by more than 2.8-fold 
in the T4-2 cell colonies than in the S-1 acini (Fig. 3 e). 
 
Function Blocking β1-Integrin Antibodies Cause Dramatic Phenotypic Reversion of the T4-
2 Cells 
 
Since T4-2 cells had both a higher total level and an elevated ratio of cell surface β1- to β4-
integrins, we wondered whether the aberrant malignant behavior may be a reflection of the 
changes in these integrins. Accordingly, we examined the consequences of treatment in 3-D with 
varying concentrations of a previously characterized rat monoclonal β1-integrin antibody (clone 
AIIB2) which has been shown to inhibit ligand binding (Werb et al., 1989). This antibody caused 
massive apoptosis in S-1 cells, as shown previously (Howlett et al., 1995), while T4-2 cells were 
refractory (Fig. 4). Remarkably however, in addition to resistance to apoptosis, almost all the 
antibody-treated T4-2 tumor cells assumed a morphology which was indistinguishable from that 
observed in S-1 cultures and was discernible as early as 4 d after incubation. When examined 
by light microscopy after 12 d, these cultures appeared as if they had truly reverted to a 
“nonmalignant” phenotype. We therefore cryosectioned the colonies and examined their 
morphology by immunofluorescence confocal microscopy. As markers of normal acinar 
formation, we examined both cytoskeletal organization and superimposition and distribution of 
cadherins and catenins. Sections of S-1 acini revealed uniform and polarized nuclei (stained with 
propidium iodide; red), well-organized filamentous actin (FITC phalloidin; green) (Fig. 5 a), and 
uniformly superimposed E-cadherin and β-catenin at the lateral cell–cell junctions (Fig. 5 b). In 
contrast, untreated or IgG-treated tumor cells had polymorphic nuclei and a grossly disorganized 
actin cytoskeleton, visualized as random, hatched bundles (Fig. 5 a’). Additionally, E-cadherin 
and β-catenin were no longer colocalized (Fig. 5 b’). In contrast, β1-treated T4-2 cells (referred 
to as T4-β1) revealed striking rearrangements of cytoarchitecture as demonstrated by their well-
organized actin (Fig. 5 a’’), and cytokeratin 18 intermediate filament (not shown) networks. 
Furthermore, organized adherens junctions became evident in T4-β1 acini (Fig. 5 b’’) and were 
accompanied by the re-establishment of E-cadherin–catenin complexes (not shown). These 
changes were shown to occur in greater than 95% of the tumor colonies treated with blocking 
antibody, as quantified by analyzing the numbers of disorganized vs organized spheroids in 
relation to the S-1 and the mock-treated T4-2 cells (Fig. 5 c). Viability and growth assays 
conducted on cells grown as monolayers ruled out toxicity (not shown). Interestingly, while 
treatment with the inhibitory β1-integrin antibody reduced cell adhesion and retarded the rate of 
cell proliferation when T4-2 cells were grown in two-dimension, culture in a three-dimensional 
reconstituted basement membrane was required for complete expression of the reverted 
phenotype (not shown). 
 
An examination of markers of proliferation and cell cycle status in T4-β1 cells revealed that they 
were growth arrested as indicated by both a decrease in thymidine incorporation and the size of 
the acini which was now composed of only 6–8 cells, similar to that observed for S-1 cells (Fig. 
5, d and e). This was in marked contrast to the average of 18–22 cells observed for nontreated 
T4-2 tumor colonies and the high mean number of T4-2 nuclei which incorporated 
[3H]thymidine (Fig. 5, d and e). T4-β1 colonies also had dramatically decreased cyclin D-1 
levels (Fig. 5 f) again comparable to that seen in S-1 cultures and markedly reduced Ki-67 levels 
(not shown), suggesting that most reverted cells had exited the cell cycle and therefore 
had a reduced propensity to proliferate. 
 
Cryosections of T4-β1 colonies incubated with antibodies against either collagen IV (Fig. 5 g’) 
or laminin (not shown) revealed deposition of a basally distributed, almost continuous basement 
membrane, with characteristics similar to that observed in the S-1 acini (Fig. 1 b). In contrast, 
punctuate and inversely polarized collagen IV (Fig. 5 g) and laminin immunostaining (not 
shown) were observed in the mock-treated tumor colonies. Thus, these tumor cells had retained 
the ability to deposit a basement membrane and to form polarized structures if the correct 
structural cues could be received. 
 
The Inhibitory β1-Integrin Activity Is Necessary for Phenotypic Reversion 
 
The AIIB2 monoclonal antibody (mAb) recognizes a region connecting the two putative 
extracellular ligand binding sites of the β1-integrin receptor, thereby inducing a conformational 
change consistent with inhibition of receptor activity (Takada and Puzon, 1993). To distinguish 
between integrin binding per se or a requirement for inhibition of signaling, we examined 
whether the T4-2 cells would phenotypically revert upon treatment with a nonfunctional (neither 
activating nor inhibiting) anti–β1-integrin mAb (clone DF5; Korhonen et al., 1991), an alternate 
inhibitory anti–β1-integrin mAb (clone JB1a or J10; Stupack et al., 1991), and an activating anti–
β1-integrin mAb (clone TS2/16; Weitzman et al., 1995), whose epitope was mapped to the same 
region as the AIIB2 antibody (Takada and Puzon, 1993). Only the β1-integrin function blocking 
antibodies were found to be capable of inducing phenotypic reversion of the T4-2 cells (Table I), 
implying that overexpression or altered signaling through a β1-integrin–specific pathway is at 
least in part responsible for the malignant phenotype of these tumor cells. To investigate the 
possibility that the inhibitory antibodies may have facilitated reversion by inducing clustering of 
the integrin receptors by divalent mAb-mediated cross-bridging, we purified the rat IgG1 AIIB2 
mAb and made AIIB2 Fab fragments (Miyamoto et al., 1995a,b). Significantly, both the purified 
AIIB2 mAb and its Fab fragments were capable of inducing the same phenotypic reversion of 
the T4-2 tumor cells (Table I), indicating that it was the β1-integrin function at the cell surface 
that needed to be reduced for reversion to occur, rather than augmentation of integrin signaling 
by receptor clustering per se. 
 
The Reversion Is Phenotypic and Reversible 
 
To distinguish between a reversible, microenvironmentally induced change as opposed to 
selection of possible nonmalignant contaminants or genetically altered mutants, we undertook a 
series of “reversion rescue” studies. Despite two rounds of reversion, rescue, monolayer 
propagation, and reculturing in 3-D, these cells were able to resume their original tumorigenic 
phenotypes when cultured in the absence of antibody (Fig. 6). 
 
 
 
 
Treatment with b1-Inhibitory Antibody Is Sufficient to Significantly Reduce Malignancy 
In Vivo 
 
To find out whether phenotypic reversion of tumor cells would be sufficient to reduce 
tumorigenicity in vivo, we injected tumor cells treated in suspension with β1-integrin 
blocking mAb, mock mAb, or no treatment for 3 h, as well as S-1 cells into nude mice. Within 
two weeks small nodules were observed in all injected sites including the S-1 controls (not 
shown). Whereas these nodules regressed rapidly in the S-1 and T4-β1 groups, actively growing 
tumors were observed in greater than 75–90% of the mock mAb or vehicle-treated T4-2 mice. 
Upon sacrifice we observed both a significantly reduced tumor number and tumor size in the T4-
β1 group (Table II). These data suggest that “normalization” of the tumor cell phenotype in 
culture has a counterpart in vivo where the malignant potential is reduced or lost. 
 
Malignant Conversion Is Associated with Alterations in α6- and β4-Integrins 
 
The ability of T4-β1 cells to re-form a basally organized basement membrane (Fig. 5 g’) 
indicated the re-establishment of acinar polarity. Polarity has been shown to be associated 
with a basal localization of α6/β4-integrin heterodimers in keratinocytes (DeLuca et al., 1994). 
T4-β1 reverted acini had polar, basally localized α6- and β4-integrins (compare Fig. 7, a–7 a’), 
increased cell surface β4-integrin heterodimers (Fig. 7 b), and higher p21cip,waf-1 levels 
(Fig. 7 c). These findings showed that the β1-integrin signaling pathway was not only 
interconnected with catenin-E-cadherin adherens junction assembly, but was also connected 
to the α6/β4-integrin signaling pathway. We therefore examined whether an alteration of α6/β4 
signaling in the nonmalignant cells might lead to abrogation of growth control, disruption of 
morphogenesis and loss of polarity. We used clone 3E1 (Hessle et al., 1984), a β4-integrin mAb 
that was shown to influence the function of colon adenoma and prostatic carcinoma cells (Jewell 
et al., 1995), and a protocol similar to that described for the β1-integrin inhibitory antibody 
studies. Treatment of S-1 cells with this antibody led to the abrogation of normal morphogenesis 
and loss of growth control. Thus, β4-integrin mAb-treated S-1 cells formed disorganized, large 
structures similar to T4-2 colonies (Fig. 7 e vs 7 d’). Interestingly the treatment had little or no 
effect on T4-2 colonies (not shown). The heterodimer partner for β4 is the α6-integrin 
(Sonnenberg et al., 1988a). Treatment of nonmalignant cells with GoH3 (Sonnenberg et al., 
1988b), an α6-integrin function-blocking antibody, led to similar results (not shown). These 
findings suggest that the α6/β4 pathway not only influences morphogenesis but is also involved 
in growth regulation in nonmalignant MEC’s. Furthermore, these results support the notion that 
the tumorigenic conversion of the HMT-3522 cells may be associated with an alteration in the 
α6/β4 signaling pathway. If this were so, then treatment of T4-α1 acini with β4 function-altering 
antibodies (or simultaneous treatment with β1 and β4 function-altering antibodies) should not 
alter the T4-β1 reverted phenotype. This in fact was found to be the case (not shown). 
 
Discussion 
 
The use of a 3-D BM assay and two related human MEC lines, one phenotypically “normal” and 
the other malignant, have allowed us to examine the fundamental role of integrins and their 
intimate relationship to adherens junctions in the regulation of growth and tissue morphogenesis. 
The results described in this paper demonstrate not only that misregulation of integrins may play 
a causal role in the expression of malignancy in human epithelial breast cells, but also that 
manipulations from the cell surface (such as modification of the transmembrane signaling 
receptors), can restore tissue form and function and reduce tumorigenicity in vivo. Thus, 
analogous to the effects following retinoid treatment of leukemias, cell surface ECM-receptor 
manipulations may offer a plausible alternative therapeutic modality for solid epithelial tumors. 
 
Our results showed that the T4-2 tumorigenic cells have increased β1-integrin expression and 
cell surface levels which are associated with loss of growth control and perturbed 
morphogenesis. Moreover, a reduction of β1- cell surface integrin activity was found to be 
sufficient to revert this tumor phenotype. These observations are consistent with the reciprocal 
relationship shown to exist between proliferation and differentiation and changes in levels of 
β1-integrins in keratinocyte cells (Jones et al., 1995), and the anchorage-free growth described 
for kidney cells overexpressing a downstream integrin signaling protein (Frisch et al., 1996). 
Overexpression and perturbed signaling through β1-integrin heterodimers have previously been 
reported in primary and metastatic cancers of the breast, colon, skin, and prostate (Cress et al., 
1995; Fujita et al., 1995; Leppa et al., 1995; Mortarini et al., 1995; Shaw et al., 1996). Enhanced 
β1-integrin expression was also shown to be associated with increased tumor aggressiveness, 
invasiveness, and metastatic potential, and was found to correlate with decreased patient survival 
(Friedrichs et al., 1995). However, a direct effect of the altered integrin expression on the tumor 
phenotype was not demonstrated in these studies, although our results may offer a plausible 
explanation for this relationship. Furthermore, the reported inhibition of invasion and metastasis 
of bladder and gastric carcinoma cells, by inhibitory β1-integrin antibodies or Arg-Gly-Asp 
peptides may be by a mechanism similar to that described in this paper (Saiki et al., 1990; Fujita 
et al., 1992). 
 
Despite dramatic differences in morphology, both the nonmalignant and tumorigenic HMT-3522 
cell lines expressed comparable levels of cell–cell adhesion proteins, but the ability to form 
cytoskeletal-associated adherens complexes was found to be compromised in the T4-2 cells. This 
is a condition which has been shown to characterize mammary carcinoma in situ and has been 
described for several aggressive metastatic breast cancers in vivo and cell lines in culture 
(Takeichi, 1993; Birchmeirer and Behrens, 1994; Sommers, 1996). By inhibiting tumor cell β1-
integrins we were able to rescue adherens junction assembly and revert the tumor phenotype of 
the T4-2 cells. These results are in agreement with the metastasis-suppressor/epithelial-
promoting role of enhanced cell–cell interactions previously shown in metastatic MB-435S/1 
breast cells (Frixen et al., 1991) and in HeLa cells (Doyle et al., 1995) transfected with cell 
adhesion molecules. These observations also emphasize the plasticity of cell–cell junction 
perturbations, and establish a definite link between integrin signaling, adherens junction 
assembly and the coordinated formation of a differentiated tissue structure, as has been 
previously implied by studies in keratinocytes and kidney cells (Hodivala et al., 1994; Ojakian 
and Schwimmer, 1994; Schoenenberger et al., 1994; Braga et al., 1995). While our findings 
suggest an integrated mechanism, the key intermediates still need to be identified, although 
perturbed adherens junction assembly can be restored by kinase inhibitors suggesting down-
stream signal transduction molecules are involved (Kinch et al., 1995). The possibility that 
cytoskeletal proteins such as fascin, a new β-catenin–binding protein which competes against 
junction assembly, and is thought to interact with the actin cytoskeleton to promote filament 
bundling and enhance cell motility, may play a role is intriguing and is under investigation (Tao 
et al., 1996). Also, whether a manipulation of the catenin-E-cadherin pathway would reciprocally 
affect integrins, or whether direct restoration of adherens assembly would be sufficient to lead to 
phenotypic reversion and inhibition of tumor formation in this system remain important 
questions. 
 
Polarity is associated with a basal localization of α6/β4-integrin heterodimers in keratinocytes 
(DeLuca 1994), which has been shown to direct intermediate filament organization (Spinardi et 
al., 1993; Guo et al., 1995), while its activity correlates with an increase in the level of p21cip,waf-1 
(Clarke et al., 1995), a gene important in growth arrest (Harper et al., 1993). Our data showing 
reorganized intermediate filaments, increased levels of p21cip,waf-1 and polarized α6- and β4-
integrins in T4-β1 acini, are consistent with these findings and emphasize the existence of 
coordinate β1–β4-integrin pathway interactions. Since we showed that α6- and β4-integrin 
perturbing antibodies were able to disrupt normal MEC cell morphogenesis, this also strongly 
implicates α6/β4-integrins in establishing mammary gland morphogenesis and tissue 
organization, as has been previously reported for kidney cells (Sorokin et al., 1990; Matter and 
Laurie, 1994) and in β4-integrin knockout mice (Dowling et al., 1996). How these interactions 
occur has yet to be determined although a role for actin and intermediate filament-associated 
proteins, interacting with the β4-integrin cytoplasmic tail, such as that described for neural 
BPAG1 should be considered (Yang et al., 1996). Finally, because we were unable to perturb the 
morphogenesis induced by β1-integrin inhibition in the T4-β1 reverted acini either by sequential 
or simultaneous incubation with function-altering β4-integrin antibodies, this indicates to us that 
a genetic defect in a facet of α6/β4-integrin signaling pathway may indeed be responsible for the 
observed loss of growth control and tissue organization observed in the T4-2 cells. Further 
experiments will be required to clarify the validity of this argument.  
 
We used a well studied parameter of cell cycle progression, cyclin D1, and of quiescence, 
p21cip,waf-1, in addition to standard DNA replication and Ki-67 assays, to determine how the 
reverted tumor cells compared to functionally normal acini. By all these criteria, T4-β1 revertant 
colonies behaved like growth-arrested S-1 acini. It was also clear from these studies that the 
formation of a BM accompanied the cessation of growth, confirming our previous findings of an 
inverse relationship between the presence of a BM and proliferation (Petersen et al., 1992; 
Howlett et al., 1994; Desprez et al., 1995). It is therefore plausible that the repression of 
tumorigenicity in vivo, as documented in these studies may have been directly related to the 
observed growth arrest in culture. Thus, it is reasonable to postulate that it is the balance of 
signals transduced by the β1- and β4-integrin receptors (or the corresponding α-integrin subunits) 
that allows these breast cells to sense their microenvironment appropriately and drive tissue 
organization and function. Therefore, integrins must function in concert with growth factor 
signaling pathways to determine the decision to grow or to undergo morphogenesis. Very 
recently, Sastry et al. (1996) overexpressed chimeric α5- and α6/β1-integrins in quail muscle 
cells and concluded that it is the cytoplasmic domain of these integrins which determines 
proliferation or growth arrest. Clearly then both direct and indirect evidence in the literature 
points to the fact that integrins, much like other biological parameters, are cell and tissue context 
specific. While the detailed molecular mechanism of β1-integrin signaling in breast cells remains 
to be elucidated, it is safe to conclude that a change in the surface-associated β1-integrin sets into 
motion global changes in growth and higher order tissue organization. The model system 
described here offers the opportunity to elucidate how β1- and α6/β4-integrin heterodimers, 
catenin-cadherin adherens junction proteins, and growth factor pathways communicate 
within and between epithelial cells in the 3-D tissue.  
 
The demonstrated plasticity of T4-2 cells, their ability to revert to a near normal phenotype and 
remain quiescent for up to one month in culture, as well as their reduced tumorigenicity in vivo 
is reminiscent of the “reversion” of mouse teratocarcinoma cells by a normal embryonic 
microenvironment. In these seminal experiments, embryonal carcinoma cells which were fused 
with normal blastocysts were able to give rise to phenotypically normal, genetically mosaic mice 
(Mintz and Illmensee, 1975; for review see Mintz and Fleischman, 1981). While the conclusion 
of these studies was that the teratocarcinoma cells did not possess cancer-associated genetic 
defects, we show in our system that despite the presence of genetic defects they could be 
restrained by the normal tissue structure. A similar dominant, tumor suppressor role of the 
embryonic microenvironment was shown by our previous work in which active pp60src 
constructs attached to a lacZ gene, packaged in a replication-defective virus, when injected into 
stage 24 chick embryos appeared as apparently normal blue cells in a well formed background of 
feathers and tissues (Stoker et al., 1990). Significantly, once these cells were removed from the 
embryos, trypsinized and placed in culture, they became rapidly transformed (Boudreau et al., 
1995a). These findings may also provide a possible mechanistic explanation for the poorly 
understood phenomenon of both spontaneous breast tumor reversion, tumor cell dormancy, and 
the sporadic occurrence of an auxiliary nodal metastasis in which a true ductal carcinoma in situ 
(DCIS), complete with a central necrosis and a surrounding intact basement membrane is 
recapitulated (Barsky et al., 1994). 
 
In conclusion, our results show that changes in tissue structure are critical for the expression of 
the malignant phenotype and that ECM receptors are important modulators of this effect. 
Furthermore, these data underscore the concept that it is the relative distribution and proportion 
of cell surface integrins (undoubtedly in cooperation with other receptors at the cell surface) and 
their integrated down-stream events which maintain the structural homeostasis of breast and 
possibly other epithelial tissues. Therefore, tumor cells need not have lost their ability to respond 
to ECM-generated signals, but rather alterations in the level of the integrated signals can lead to 
aberrant behavior. Our results may also have a bearing on why some tumor cells retain strong 
cell-ECM interactions: integrin switching may promote enhanced survival in alternate 
microenvironments encouraging metastasis. 
 
Most fundamentally, these studies show that despite a number of prominent mutations, 
amplifications, and deletions, signaling events which are linked to the maintenance of normal 
tissue architecture are sufficient to abrogate malignancy and to repress the tumor phenotype. It is 
thus fair to state that cellular and tissue architecture act as the most dominant tumor-suppressor 
of all, and that the phenotype can—and does—override the genotype as long as the tissue 
architecture is maintained. These results may explain why breast cancer takes so long to develop 
even in individuals with inherited susceptibility. Finally, these studies should further aid in the 
development of therapeutic peptides and antibodies for the treatment of breast and other solid 
tissue malignancies. 
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Figures and Tables 
 
FIGURE 1 
 
 
Characterization of the HMT-3522 human breast cancer model. (a and a’) Phase contrast 
micrographs of nonmalignant S-1 cell colonies (a) and tumorigenic T4-2 cell colonies (a’) 
viewed directly inside EHS for morphology: S-1 cells formed spherical structures reminiscent of 
true acini (a), whereas T4-2 cells formed large irregular colonies (a’). (b and b’) Immunostaining 
for basement membrane components: S-1 acini (b) stained for basement membrane proteins at 
the cell-ECM junctions as expected, while basement membrane deposition in tumor colonies (b’) 
was clearly disorganized and no longer polarized. Comparable results were obtained for laminin 
(not shown). (c and c’) Confocal fluorescence microscopy of cryosectioned colonies 
immunostained for E-cadherin: S-1 acini (c) stained for E-cadherin primarily at the cell–cell 
junctions as is typically observed in normal breast sections. The T4-2 colonies (c’) showed 
punctate, dispersed membrane and intracellular staining. (d) The β-catenin–E-cadherin 
interaction ratio as a measure of adherens junction assembly: There was a 50% decrease in β-
catenin protein coprecipitating with E-cadherin in T4-2 cells as compared to S-1 acini. Data are 
expressed as a ratio of β-catenin to E-cadherin densitometric measurements from duplicates of 
two separate experiments. Similar results were observed for α-catenin (not shown). (e) 
Immunoblots of total levels of E-cadherin, a-catenin, and b-catenin: There were comparable 
levels of all three adherens proteins in S-1 acini and T4-2 colonies. (f and g) Percent of 
thymidine and Ki-67 labeling in S-1 acini and T4-2 colonies, expressed as thymidine and Ki-67 
labeling indices from 3–4 separate experiments: Greater than 90% of the S-1 acini were 
growth arrested (f), and had exited the cell cycle (g) whereas T4-2 colonies were still actively 
growing (f) and continued to cycle (g). All cultures were analyzed after 10–12 d inside EHS. 
Bars: (a and a’) 16 mm; (b and b’) 25 mm; (c and c’) 8 µm. 
 
 
 
FIGURE 2 
 
 
Immunofluorescence characterization of integrins in the HMT-3522 cells in 3-dimensional 
cultures. (a–d) Cryosections of S-1 acini and (a’–d’) T4-2 colonies, immunostained and 
examined by confocal fluorescence microscopy for localization of β1- (a and a’), β4- (b and b’), 
α6- (c and c’), and α3-integrin (d and d’) localization: β1-, β4-, and α6-integrins were targeted to 
the cell-ECM junction in the S-1 acini (a–c), in contrast, in T4-2 colonies (a’–c’) this polarized-
basal distribution was lost. S-1 acini exhibited basolateral α-3 integrins (d), whereas T4-2 
colonies (d) demonstrated disorganized plasma membrane and cytosolic expression of this 
integrin. All cultures were analyzed after 10–12 d inside EHS. Bars: (a–d and a’–d’) 16 µm. 
 
 
 
 
 
 
 
 
 
 
FIGURE 3 
 
 
 
Biochemical characterization of integrins in the HMT-3522 cells after culture in 3-dimensions. 
(a and b) Western analysis of β1- and β4-integrins: Total cell lysates of S-1 and T4-2 colonies 
showed elevated expression of β1- (a) and β4-integrins (b) in the tumor cell colonies. (c and d) 
Cell surface expression of β1-and β4-integrin heterodimers using biotinylation: Tumor colonies 
had 12.5% higher plasma membrane levels of β1- (c) but 60% lower levels of β4-integrin 
heterodimers (d) than S-1 acini. (e) Relative scan units (RSU) showing relative colony surface 
levels of β1- and β4-integrin heterodimers: There was a 2.8-fold relative increase in the ratio of 
β1-integrins to β4-integrin on the colony cell surface of T4-2 colonies as compared to the S-1 
acini. All cells were analyzed after 10–12 d inside EHS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4 
 
 
Apoptosis induction in HMT-3522 cells by inhibitory β1-integrin function blocking antibodies. 
Apoptotic labeling indices calculated for S-1 and T4-2 cultures treated with inhibitory β1-
integrin antibodies for 4 d in 3-dimensional cultures: Greater than 70% of S-1 cells were induced 
to undergo apoptosis within 4 d of incubation with β1-integrin function blocking antibody (S-1 
β1) while the level of basal apoptosis was less than 5% in the isotype controls (S-1 IgG). In 
contrast T4-2 cells similarly treated (T4 β1) were refractory and had an apoptosis rate 
comparable to basal levels (T4-2 IgG). Results are the mean and SE of 3–6 separate experiments 
of duplicates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 5 
 
 β1-inhibitory antibody treatment of tumor cells leads to the formation of reverted acini. (a–a’’) 
Confocal fluorescence microscopy images of F actin: Both the S-1 (a) and T4-β1 reverted acini 
(a’’) showed basally localized nuclei (propidium iodide) and organized filamentous F-actin 
(FITC), while T4-2 mock-treated colonies (T4-2 IgG) had disorganized, hatched bundles of actin 
and pleiomorphic nuclei (a9). (b–b’’) Confocal immunofluorescence microscopy images of E-
cadherin (FITC) and β-catenin (Texas red): In S-1 (b) and T4-β1 reverted acini (b’’), E-cadherin 
and β-catenins were colocalized and superimposed at the cell–cell junctions. (c) Quantitative 
analysis of tumor cell conversion efficiency by β1-integrin function blocking antibodies: Greater 
than 95% of S-1 and T4-β1 colonies were scored as organized, while 97% of T4-2 IgG colonies 
were considered disorganized. Other reversion criteria, such as scoring for actin and cadherin 
organization also yielded comparable results (not shown). (d) Cell number per colony in S-1 
acini, T4-2 IgG colonies and T4-β1 acini from 3–5 experiments: Both S-1 and T4-β1-revertant 
acini contained 6–8 cells, while T4-2 IgG tumor colonies contained 18–22 cells when scored 
after 10–12 d (d). (e) Percent of thymidine-labeled cells in S-1, T4-2 IgG, and T4-β1 colonies: 
While a high percentage of T4-2 IgG colonies (greater than 30%) were still actively growing, the 
T4-2 β1 revertant acini had a greatly reduced growth rate similar to that observed in the S-1 
acini. (f) Immunoblot of cyclin D1 levels in S-1, T4-2, T4-2 IgG, and T4-β1 colonies: The level 
of D1 cyclin wasclearly decreased to the level of S-1 acini after β1 inhibitory antibody treatment. 
(g and g’) Collagen IV deposition as an indicator of basement membrane organization: T4-β1 
reverted acini (g’) deposited an organized collagen IV-containing BM at the cell-ECM junctions, 
similar to that observed in S-1 acini (see Fig. 1 b). Note the contrast with T4-2 mock–treated 
tumor colonies (g). (Comparable results were obtained for laminin, not shown.) All cultures were 
analyzed after 10–12 d inside EHS. Bars: (a–a’’ and b–b’’) 16 µm; (g and g’) 25 µm. 
 
FIGURE 6 
 
 
 
Phenotypic reversion as opposed to selection. Phase contrast micrographs of T4-2 cells grown in 
the presence of anti–β1-integrin function blocking antibody (T4 β1), mock antibody (nonspecific 
IgG’s) (T4-2 IgG) or no antibodies (T4-2) viewed directly inside EHS: Despite two rounds of 
treatment, these antibody reverted cells were able to resume their original tumorigenic 
phenotypes when cultured in the absence of antibody. All cultures were analyzed after 10–12 d 
inside EHS. Bar, 50 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 7 
 
 
 
Alteration of α6/β4-integrin signaling in S-1 cells leads to the formation of disorganized 
colonies. (a and a’) Confocal fluorescence microscopy of double immunostaining for α6- (Texas 
red) and β4-integrins (FITC): T4-β1 revertant acini (a’) showed basally polarized α6- and β4-
integrins, while T4-2 mock–treated (T-4 IgG) colonies (a) demonstrated disorganized, 
nonpolarized expression. (b) Cell surface expression of β4-integrin heterodimers using 
biotinylation: Tumor colonies had lower cell surface levels of β4-integrin heterodimers (60% 
lower) relative to the S-1 acini (see Fig. 3 d), which were restored in the T4-β1 reverted acini 
(40% higher) relative to the T4-2 colonies. (c) Immunoblot of p21cip,waf-1 levels in T4-2 IgG and 
T4-β1 colonies: The level of p21 protein was clearly increased in the T4-β1 reverted acini. (d and 
d’) Phase contrast micrographs of S-1 nonmalignant acini (d) and tumorigenic T4-2 colonies (d’) 
viewed directly inside EHS: S-1 cells formed spherical structures (d), whereas T4-2 cells formed 
large, irregular colonies (d’). (e and e’) Phase contrast micrographs of S-1 nonmalignant cells 
treated with function altering β4-integrin antibodies (e) and tumorigenic T4-2 cells treated with 
function blocking β1-integrin antibodies (e’) viewed directly inside EHS: S-1 cells treated with 
β4-integrin antibodies formed large, irregular colonies (e), while T4-2 cells treated with β1-
integrin function-blocking antibody (e’) formed spherical structures similar to S-1 acini (see Fig. 
1 a). All cultures were analyzed after 10–12 d inside EHS. Bar, 16 µm. 
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